Literature DB >> 31147310

Multimodality imaging studies of intraductal tubulopapillary neoplasms of the pancreas.

Hye Jin Kim1, Mi-Suk Park2, Taek Chung3, Bohyun Kim4, Jei Hee Lee4, Jai Keun Kim4.   

Abstract

PURPOSE: We aimed to investigate multimodality imaging findings of intraductal tubulopapillary neoplasms (ITPN) of the pancreas.
METHODS: This study was approved by the institutional review board with waived informed consent. A total of eight patients were histopathologically diagnosed with pancreatic ITPN in a single institution over a 6-year period. The imaging findings of dynamic contrast-enhanced computed tomography (CT), magnetic resonance cholangiopancreatography (MRCP), endoscopic ultrasonography (EUS), and positron emission tomography-computed tomography (PET-CT) were reviewed and correlated with clinicopathologic findings.
RESULTS: Histopathologically, an invasive carcinoma component was found in 5 of 8 patients (62.5%). The median diameter of the lesions and the main pancreatic ducts were larger in ITPN with invasive carcinoma (19 mm, 13.3-98.0 mm and 13 mm, 5.9-16.3 mm, respectively) than in ITPN without invasive carcinoma (13 mm, 12.7-18.5 mm and 6 mm, 5.6-6.1 mm, respectively), but not significantly (lesions, P = 0.229 and main pancreatic ducts, P = 0.143). Pancreatolithiasis accompanied invasive carcinoma in 3 of 5 patients (60%). Intraductal solid tumors were demonstrated on CT (5/8, 62.5%), MRCP (5/7, 71.4%), and EUS (7/7, 100%). In addition, various imaging findings mimicking chronic autoimmune pancreatitis or pancreatic ductal adenocarcinoma were found in 3 patients (37.5%) on multimodality imaging. The lesion multiplicity and synchronous or metachronous biliary cancer occurred in 3 patients (37.5%), respectively.
CONCLUSION: Patients with associated invasive carcinoma from pancreatic ITPN may have presented a trend toward larger tumor size and dilated pancreatic duct with pancreatoliths, but the difference was not statistically significant. Further studies with a larger number of patients are needed to provide better insight into these findings. Pancreatic ITPN can show various atypical imaging findings as well as typical intraductal solid tumor on multimodality imaging. The presence of lesion multiplicity and synchronous or metachronous biliary cancer can be helpful for assisting with the diagnosis of pancreatic ITPN.

Entities:  

Mesh:

Year:  2019        PMID: 31147310      PMCID: PMC6622442          DOI: 10.5152/dir.2019.18215

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  4 in total

1.  Total Pancreatectomy with Splenectomy for Multifocal Intraductal Tubulopapillary Neoplasm (ITPN) of the Pancreas Associated with Invasive Component: Report of a Rare Case.

Authors:  Christoforos Kosmidis; Nikolaos Varsamis; Stefanos Atmatzidis; Georgios Koimtzis; Stylianos Mantalovas; Georgios Anthimidis; Eleni Georgakoudi; Christina D Sevva; Katerina Zarampouka; Danai Chourmouzi; Ariadni Leptopoulou; Sofia Baka; Maria Kosmidou
Journal:  Am J Case Rep       Date:  2020-07-10

2.  Intraductal tubulopapillary neoplasms of the pancreas and biliary tract: The black swan of hepatobiliary surgery.

Authors:  Jilyan Decker; Amanda Cavanaugh; Megan Brown; Saverio Ligato; Oscar Kenneth Serrano
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-11-30

3.  Imaging features of intraductal tubulopapillary neoplasm of the pancreas and its differentiation from conventional pancreatic ductal adenocarcinoma.

Authors:  Ekaterina Khristenko; Thomas Hank; Matthias M Gaida; Hans-Ulrich Kauczor; Thilo Hackert; Miriam Klauß; Philipp Mayer
Journal:  Sci Rep       Date:  2022-09-16       Impact factor: 4.996

Review 4.  Intraductal tubulopapillary neoplasm (ITPN) of the pancreas: a distinct entity among pancreatic tumors.

Authors:  Gaetano Paolino; Irene Esposito; Seung-Mo Hong; Olca Basturk; Paola Mattiolo; Takuma Kaneko; Nicola Veronese; Aldo Scarpa; Volkan Adsay; Claudio Luchini
Journal:  Histopathology       Date:  2022-05-27       Impact factor: 7.778

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.